Hispanic patients with multiple myeloma (MM) were diagnosed at a younger age and were more likely to die from their disease compared with non-Hispanic patients, according to the results of a retrospective study presented at the Annual Meeting of the Society of Hematologic Oncology (SOHO).

“Clinical characteristics and outcomes of MM are not well understood in Hispanics, which represent one of the fastest growing populations in the US,” the authors wrote in their presentation.

The retrospective study evaluated data from 5115 Hispanic and 22,426 non-Hispanic patients from the Texas Cancer Registry who were diagnosed with MM between 1996 and 2016.


Continue Reading

Compared with non-Hispanic patients, Hispanic patients were more likely to be younger compared with non-Hispanic patients, with a mean age of 65.2 and 68.0, respectively (P <.001). Among Hispanic patients, 13.12% were aged 50 or younger and 35.84% were aged 51 to 65, whereas there were 8.60% of non-Hispanic patients aged 50 years or younger and 30.37% who were aged 51 to 65 (P <.001).

Patients who were Hispanic were also less likely to undergo transplant at 5.80% compared with 7.38% of patients undergoing transplant who were non-Hispanic (P <.001).

Shorter overall survival was significantly associated with Hispanic ethnicity, including among Hispanic White (hazard ratio [HR], 1.15; 95% CI, 1.07-1.23; P =.001) and Hispanic American Indian (HR, 1.81; 95% CI, 1.07-3.08; P =.028) patients. Patients who were non-Hispanic Black were also more likely to die from MM (HR, 1.11; 95% CI, 1.04-1.18; P =.001) compared with non-Hispanic White patients.

Increasing older age was significantly associated with shorter survival, with an HR of 1.66 for the 51-65 age group (95% CI, 1.47-1.86; P =.001), 2.19 for the 66-79 year age group (95% CI, 1.93-2.47; P =.001), and 3.38 for ages 80 and older (95% CI, 2.96-3.84; P =.001). Female sex was associated with longer survival (HR, 0.86; 95% CI, 0.82-0.91; P =.001).

The authors concluded that “these data highlight the need for improved access to equitable healthcare and clinical trials for Hispanics.”

Reference

Shaikh H, Nhim V, Bencomo-Alvarez AE, et al. Disparities in multiple myeloma between Hspanics and non-Hispanics—real world outcomes. Presented at: Annual Meeting of the Society of Hematologic Oncology (SOHO); September 28-October 1, 2022. Abstract MM-281.